09:00 uur 19-11-2024

Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 2025

  • In addition, Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium, discussing nizubaglustat’s profile and plans for global Phase 3 studies
  • Six presentations will showcase nizubaglustat’s therapeutic potential for Lysosomal Storage Disorders, including Niemann-Pick disease type C (NPC) and GM1/GM2 gangliosidoses
  • WORLDSymposium™ 2025 takes place from February 3 to 7 in San Diego, California

LEIDEN, Netherlands–(BUSINESS WIRE)– Azafaros B.V., a clinical-stage biotechnology company focused on rare diseases and lysosomal storage disorders, today announced that advancements with its lead asset, nizubaglustat, will feature prominently on the agenda at the upcoming WORLDSymposium™ 2025, the pre-eminent conference on lysosomal diseases.

An oral presentation will highlight the results of the company’s Phase 2 RAINBOW study. Additionally, five poster presentations (one being a collaboration with patient organisations) will showcase nizubaglustat’s promise as an investigational therapy for NPC and GM1/GM2 gangliosidoses. A satellite symposium will further discuss the clinical path for the development and profile of nizubaglustat, and outline plans for pivotal Phase 3 clinical trials next year.

Azafaros’ presence at the conference offers a timely platform to engage key stakeholders regarding our upcoming global Phase 3 studies for GM1 and GM2 gangliosidoses, as well as NPC. These studies, set to be conducted across major regions including the United States, Europe, Latin America, and other select countries, are anticipated to commence in 2025.

Oral Presentation:

  • The RAINBOW study, a Phase 2 investigation of nizubaglustat in Niemann-Pick Type C and GM2 gangliosidosis, will be presented in an oral session on February 6. The data underscore nizubaglustat’s potential as a therapeutic option, reinforcing Azafaros’ commitment to addressing critical unmet needs in lysosomal storage disorders.

Satellite Symposium on Nizubaglustat and Phase 3 Development

  • Azafaros will host a satellite symposium on February 4 at 12:15, creating an opportunity to engage key opinion leaders, healthcare professionals and patient advocacy organizations in Azafaros’ clinical roadmap. This forum will provide insights into the results from the RAINBOW study and outline the company’s Phase 3 global development plans for nizubaglustat.

Poster Presentations:

February 5

  • Seizures: Significant co-morbidity for patients and families living with Niemann-Pick Type C: Co-authored with the UK Niemann-Pick patient group, this poster explores the significant burden seizures impose on patients and families.
  • Nizubaglustat, a novel GCS and NLGase inhibitor significantly increases survival in a mouse model of GM1 Gangliosidosis: Preclinical data demonstrate that nizubaglustat significantly extends survival in a GM1 mouse model, providing promising insights into its potential therapeutic effects.

February 6

  • Gangliosidoses: Understanding disease evolution in GM1 and GM2: Data from PRONTO, the largest prospective natural history study in these diseases, enhance the understanding of disease progression in these rare lysosomal conditions.
  • Application of a natural history study on an investigational drug clinical development: This analysis compares data from the RAINBOW and PRONTO studies, illustrating the role of natural history studies in guiding drug development.
  • “Fact Checking” with the Patient Community: An Industry-Advocacy Collaboration for Optimizing Trial Design: This poster is the result of a collaboration between Azafaros and two US organisations, National Tay-Sachs & Allied Diseases Association (NTSAD) and the National Niemann-Pick Disease Foundation (NNPDF), as well as two UK organisations, the CATS Foundation and NPUK.

“We are honoured to present our research at such a prominent conference as the WORLDSymposium™ 2025” said Stefano Portolano, Chief Executive Officer at Azafaros. “These presentations, including the Phase 2 RAINBOW study data, reflect the promise of our late-stage asset nizubaglustat to provide a potential new therapeutic treatment to address a large unmet need for patients with certain types of lysosomal storage disorders. We look forward to highlighting important nizubaglustat data and collaborating with the medical community and patient associations dedicated to improving the lives of those impacted by these rare diseases.”

About nizubaglustat

Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC).

Nizubaglustat has received the following designations and support:

United States Food and Drug Administration (FDA)

Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC.

Orphan Drug Designations (ODD) for GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC.

Fast Track Designation and IND clearance for GM1 and GM2 gangliosidoses and NPC

European Medicines Agency (EMA)

Orphan Medicinal Product Designation (OMPD) for the treatment of GM2 gangliosidosis.

UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Innovation Passport for the treatment of GM1 and GM2 gangliosidoses.

About GM1 and GM2 gangliosidoses

GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS), resulting in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available.

About Niemann-Pick disease type C (NPC)

Niemann-Pick disease type C is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood.

About Azafaros

Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by a syndicate of leading Dutch and Swiss investors including Forbion, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.

Contacts

Azafaros B.V.

Email: info@azafaros.com
www.azafaros.com

Check out our twitter: @NewsNovumpr